New molecular imaging agent traces advanced prostate cancer

the ONA take:

Antiandrogen hormonal therapy can be an important part of preventing further disease progression for patients with metastatic prostate cancer. However, some cancers do not respond to the treatment. An imaging technique developed at Johns Hopkins University in Baltimore, Maryland, F-18 DCFBC PET/CT, uses a unique small-molecule PET agent to search for and attach to prostate-specific membrane antigen. The technique was developed in an effort to improve clinical decision making for patients who are not responding to androgen deprivation therapy.

New molecular imaging agent traces advanced prostate cancer
New molecular imaging agent traces advanced prostate cancer
Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment.
READ FULL ARTICLE From News Medical
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs